{'fraction_non_alphanumeric': 0.02011704462326262, 'fraction_numerical': 0.0073152889539136795, 'mean_word_length': 5.511904761904762, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
COMPARISON OF EFFICACY OF FIVE VARIOUS COMMERCIAL PRODUCTS OF CIPROFLOXACIN AGAINST STAPHYLOCOCCUS AUREUS AND PSEUDOMONAS AERUGINOSA

A study was undertaken to evaluate the efficacy of five various commercial products of ciprofloxacin (a broad spectrum antibiotic), manufactured by different pharmaceutical companies. The drug was evaluated for their performance based on equivalent MIC breakpoint, which is a measure of efficacy of drugs against Staphylococcus aureus ATCC6538 and Pseuomanas aeruginosa ATCC25668 when tested in vitro. The data showed variation for all manufacturers with significant difference (p <0.0001) in efficacy of these drugs at the final dilution level (0.02-0.1μg/μl) against P.aeruginosa. Thus the ciprofloxacin, prepared by various manufacturers are not equally efficacious in inhibiting the growth of S.aureus and P.aeruginosa. Therefore, manufacturers should pay special attention for stringent quality control of drug, and clinicians are suggested to use these antibiotics judiciously in the treatment of patients for these infections. INTRODUCTION: Pharmaceutical products play an important role in improving the health and encouraging the well-being of every individual. These medicines bring succor in the prevention and treatment of diseases, disorders, or conditions. The three criteria considered the cornerstone for these products-quality, effectiveness, and safetyshould be demonstrated and verified prior to their rational use . However, the overuse and misuse of these products are leading to the emergence of resistance to these life-saving drugs. Consequently, it is now imperative for clinical microbiologists to provide the clinicians with accurate information required for selecting antibiotics for patient’s therapy and care . The method of choice for the clinical microbiologist for the in vitro antimicrobial susceptibility testing is still the disc diffusion method. The Kirby-Bauer technique 3 for disk susceptibility testing has been recommended by CLSI, which is approved by US FDA, and it is also recommended by WHO. Standardization of the techniques controls variation in results, and interpretation is based on a comparison the diameter of the zone of inhibition with published criteria . Nowadays, lots of pharmaceutical companies are involved in formulation and manufacturing of drugs with different trade names. It is reasonable to expect that all the drugs contain the same salt and quantity. Thus, a clinician prescribes the medicine with its trade name only . Therefore, this study reviews to find out that, is there any significant difference in the efficacy of these drugs manufactured by different companies with a focus on antimicrobial susceptibility testing against